vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and Direct Digital Holdings, Inc. (DRCT). Click either name above to swap in a different company.

Aquestive Therapeutics, Inc. is the larger business by last-quarter revenue ($13.0M vs $8.4M, roughly 1.5× Direct Digital Holdings, Inc.). Direct Digital Holdings, Inc. runs the higher net margin — -138.7% vs -244.8%, a 106.1% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs -7.4%). Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs -38.6%).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

Devolver Digital, Inc. is an American video game publisher based in Austin, Texas, specializing in the publishing of indie games. The company was founded in June 2009 by Nigel Lowrie, Harry Miller, Graeme Struthers, Rick Stults, and Mike Wilson, five executives who had been involved with Gathering of Developers and Gamecock Media Group, which published games on developer-friendly terms, but due to the high cost associated with releasing retail games saw themselves acquired and dissolved by la...

AQST vs DRCT — Head-to-Head

Bigger by revenue
AQST
AQST
1.5× larger
AQST
$13.0M
$8.4M
DRCT
Growing faster (revenue YoY)
AQST
AQST
+17.1% gap
AQST
9.7%
-7.4%
DRCT
Higher net margin
DRCT
DRCT
106.1% more per $
DRCT
-138.7%
-244.8%
AQST
Faster 2-yr revenue CAGR
AQST
AQST
Annualised
AQST
3.9%
-38.6%
DRCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AQST
AQST
DRCT
DRCT
Revenue
$13.0M
$8.4M
Net Profit
$-31.9M
$-11.7M
Gross Margin
55.2%
26.8%
Operating Margin
-221.6%
-53.4%
Net Margin
-244.8%
-138.7%
Revenue YoY
9.7%
-7.4%
Net Profit YoY
-86.8%
-434.7%
EPS (diluted)
$-0.26
$-74.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
DRCT
DRCT
Q4 25
$13.0M
$8.4M
Q3 25
$12.8M
$8.0M
Q2 25
$10.0M
$10.1M
Q1 25
$8.7M
$8.2M
Q4 24
$11.9M
$9.1M
Q3 24
$13.5M
$9.1M
Q2 24
$20.1M
$21.9M
Q1 24
$12.1M
$22.3M
Net Profit
AQST
AQST
DRCT
DRCT
Q4 25
$-31.9M
$-11.7M
Q3 25
$-15.4M
$-2.7M
Q2 25
$-13.5M
$-2.2M
Q1 25
$-22.9M
$-2.4M
Q4 24
$-17.1M
$-2.2M
Q3 24
$-11.5M
$-2.7M
Q2 24
$-2.7M
$-590.0K
Q1 24
$-12.8M
$-775.0K
Gross Margin
AQST
AQST
DRCT
DRCT
Q4 25
55.2%
26.8%
Q3 25
64.8%
27.7%
Q2 25
54.4%
35.1%
Q1 25
58.1%
29.3%
Q4 24
61.9%
32.5%
Q3 24
67.2%
38.7%
Q2 24
77.5%
27.1%
Q1 24
63.6%
22.4%
Operating Margin
AQST
AQST
DRCT
DRCT
Q4 25
-221.6%
-53.4%
Q3 25
-89.6%
-49.0%
Q2 25
-113.6%
-23.9%
Q1 25
-222.1%
-48.1%
Q4 24
-114.4%
-51.8%
Q3 24
-61.2%
-40.3%
Q2 24
0.3%
-9.4%
Q1 24
-74.3%
-12.6%
Net Margin
AQST
AQST
DRCT
DRCT
Q4 25
-244.8%
-138.7%
Q3 25
-120.6%
-33.6%
Q2 25
-135.4%
-22.2%
Q1 25
-263.0%
-28.9%
Q4 24
-143.7%
-24.0%
Q3 24
-85.0%
-29.6%
Q2 24
-13.7%
-2.7%
Q1 24
-106.4%
-3.5%
EPS (diluted)
AQST
AQST
DRCT
DRCT
Q4 25
$-0.26
$-74.97
Q3 25
$-0.14
$-0.24
Q2 25
$-0.14
$-0.23
Q1 25
$-0.24
$-0.35
Q4 24
$-0.18
$-90.17
Q3 24
$-0.13
$-0.71
Q2 24
$-0.03
$-0.16
Q1 24
$-0.17
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
DRCT
DRCT
Cash + ST InvestmentsLiquidity on hand
$728.0K
Total DebtLower is stronger
$27.5M
Stockholders' EquityBook value
$-33.7M
$-7.0M
Total Assets
$160.4M
$20.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
DRCT
DRCT
Q4 25
$728.0K
Q3 25
$129.1M
$871.0K
Q2 25
$60.5M
$1.6M
Q1 25
$68.7M
$1.8M
Q4 24
$71.5M
$1.4M
Q3 24
$77.9M
$4.1M
Q2 24
$89.9M
$1.1M
Q1 24
$95.2M
$3.3M
Total Debt
AQST
AQST
DRCT
DRCT
Q4 25
$27.5M
Q3 25
$45.0M
$10.8M
Q2 25
$45.0M
$33.5M
Q1 25
$45.0M
$32.9M
Q4 24
$32.5M
Q3 24
$45.0M
$150.0K
Q2 24
$45.0M
$34.8M
Q1 24
$45.0M
$32.4M
Stockholders' Equity
AQST
AQST
DRCT
DRCT
Q4 25
$-33.7M
$-7.0M
Q3 25
$-4.1M
$-6.7M
Q2 25
$-72.6M
$-24.6M
Q1 25
$-60.9M
$-23.3M
Q4 24
$-60.2M
$-19.7M
Q3 24
$-45.4M
$-16.7M
Q2 24
$-35.5M
$-10.5M
Q1 24
$-36.3M
$-7.5M
Total Assets
AQST
AQST
DRCT
DRCT
Q4 25
$160.4M
$20.2M
Q3 25
$163.6M
$22.5M
Q2 25
$93.7M
$23.3M
Q1 25
$102.2M
$23.8M
Q4 24
$101.4M
$26.0M
Q3 24
$110.0M
$31.3M
Q2 24
$117.6M
$48.5M
Q1 24
$129.5M
$52.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
DRCT
DRCT
Operating Cash FlowLast quarter
$-8.5M
$-1.9M
Free Cash FlowOCF − Capex
$-8.6M
FCF MarginFCF / Revenue
-65.7%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-53.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
DRCT
DRCT
Q4 25
$-8.5M
$-1.9M
Q3 25
$-12.6M
$-1.6M
Q2 25
$-7.9M
$-2.7M
Q1 25
$-23.4M
$-2.7M
Q4 24
$-6.5M
$-1.6M
Q3 24
$-11.9M
$3.0M
Q2 24
$-7.0M
$-4.4M
Q1 24
$-10.4M
$-5.7M
Free Cash Flow
AQST
AQST
DRCT
DRCT
Q4 25
$-8.6M
Q3 25
$-12.9M
Q2 25
$-8.0M
Q1 25
$-23.5M
Q4 24
$-6.5M
Q3 24
$-12.0M
Q2 24
$-7.0M
Q1 24
$-10.4M
FCF Margin
AQST
AQST
DRCT
DRCT
Q4 25
-65.7%
Q3 25
-100.6%
Q2 25
-80.2%
Q1 25
-269.9%
Q4 24
-54.8%
Q3 24
-88.3%
Q2 24
-35.0%
Q1 24
-86.4%
Capex Intensity
AQST
AQST
DRCT
DRCT
Q4 25
0.7%
Q3 25
1.8%
Q2 25
1.1%
Q1 25
1.5%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
0.2%
Q1 24
0.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AQST
AQST

Segment breakdown not available.

DRCT
DRCT

Buy Side Advertising$8.2M98%
Other$183.0K2%

Related Comparisons